

ESMO Asia Virtual Congress 2020 Industry Satellite Symposium

# Improving outcomes in early-stage and advanced *EGFR*-mutated NSCLC: emerging strategies

## (CHANNEL 1)

**SATURDAY 21 NOVEMBER** 12:00–13:30 (SGT); 05:00–06:30 (CET)/ **FRIDAY 20 NOVEMBER** 23:00–00:30 (EST)

- Symposium presentations and panel discussion recordings available for viewing
- Live audience Q&A (15 minutes)

All recordings will be available for on-demand viewing until Thursday 29 November, 2020

### **AGENDA & FACULTY**

- The value of the MDT in the management of EGFRm NSCLC Ong Boon Hean
- Improving outcomes in early-stage EGFRm NSCLC: optimising the patient journey (including panel discussion)
   Chee Lee
- Treatment strategy in advanced EGFRm NSCLC: maximising benefit for patients (including panel discussion)
   Wong Seng Weng



Chee Lee (Chair)
St George Hospital,
Kogarah, Australia



Ong Boon Hean
Duke-NUS Medical
School, Singapore



Wendy Cooper
The University of Sydney,
School of Medicine,
Camperdown, Australia



Rachel Sanborn

Providence Cancer,
Institute Franz Clinic,
Portland, USA



Wong Seng Weng
The Cancer Centre
(Singapore Medical
Group), Singapore

### AstraZeneca's commitment to sustainability



\$15.5 million
invested in
environmental
efficiency projects in

2019 (NRRGG fund)



**CPD A Lists** 

One of three companies worldwide to achieve double A listing for Climate Change and Water Security for four consecutive years



62% of our power

is sourced or generated from renewable sources



### 100% of API

(Active Pharmaceutical Ingredient) discharges from AstraZeneca sites were assessed as safe



18% reduction

in our water use since 2015



# 25% of our vehicles

in Europe, North America or Japan are hybrid or electric



AstraZeneca is investing up to \$1 billion in a commitment to become carbon neutral by 2025 and carbon negative by 2030. Find out more about AstraZeneca's commitment to sustainability at our website.

